Analyst firms · UBS · GEHC
UBS GEHC price target and rating history
GE HealthCare Technologies Inc. (GEHC) · Health Care
UBS rates GE HealthCare Technologies Inc. (GEHC) Neutral with a $69 price target, as of its latest action on May 21, 2026. It has published 7 rating actions on GEHC since April 2023, including 3 upgrades and 3 downgrades. Across 6 firms with a GEHC price target in the last 12 months, the median target is $75. UBS's $69 is 8% below that.
- Current rating
- Neutral
- Price target
- $69
- Median target, all firms
- $75
- Actions on GEHC
- 7
UBS price target on GEHC
Every UBS rating on GEHC
- May 21, 2026
- Jan 15, 2026
- May 5, 2025
- Sep 26, 2024
- Feb 12, 2024
- Nov 27, 2023
- Apr 26, 2023
How other firms rate GEHC
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Wolfe Research | Peer Perform | Oct 20, 2026 | |
| Barclays | Overweight | $85 | Oct 7, 2026 |
| Needham | Buy | $93 | Sep 22, 2026 |
| BMO Capital Markets | Market Perform | $70 | Jul 9, 2026 |
| RBC Capital Markets | Outperform | $80 | Jun 23, 2026 |
| UBS | Neutral | $69 | May 21, 2026 |
| Goldman Sachs | Neutral | $65 | Apr 30, 2026 |
Questions about UBS and GEHC
- What is UBS's price target for GEHC?
- UBS's latest stated price target for GE HealthCare Technologies Inc. (GEHC) is $69, from its action on May 21, 2026.
- What is UBS's rating on GEHC?
- UBS rates GEHC Neutral, a neutral rating, as of May 21, 2026.
- When did UBS last change its view on GEHC?
- On May 21, 2026, UBS upgrades to Neutral from Sell, price target $69.
- How does UBS's GEHC target compare with other analysts?
- Across 6 firms with a GEHC price target in the last 12 months, the median target is $75. UBS's $69 is 8% below that.
More GEHC rating histories
All UBS ratingsGEHC news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.